NRAS, NRAS proto-oncogene, GTPase, 4893

N. diseases: 611; N. variants: 17
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.800 GeneticVariation disease BEFREE Current clinical guidelines recommend mutation analysis for select codons in KRAS and NRAS exons 2, 3, and 4 and BRAF V600E to guide therapy selection and prognostic stratification in advanced colorectal cancer. 31589789 2020
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE Combined therapeutic targeted strategies are awaited in NRAS-mutated and KIT-altered melanoma and could provide additional benefit. 31833955 2020
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE Similar results were obtained for TRB CDR3s and NRAS mutants in melanoma. 31740784 2020
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease BEFREE Intra-patient heterogeneity was detected in 13.3% of patients for both BRAF and NRAS genes and was not associated with clinico-pathological characteristics of melanomas or metastases. 31774543 2020
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE Accordingly, in a cohort of 79 BRAF/NRAS double wild type cutaneous melanoma and 17 mucosal melanoma KIT mutation was assessed by Sanger sequencing of exons 9,11,13,17 and 18. 31848942 2020
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE Our findings thus show a new pathway involved in NRAS-mutant melanoma resistance and provide new opportunities for novel therapeutic options. 31549767 2020
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE Our study aims to evaluate and review other studies that present the frequency of mutations of BRAF, NRAS, and KIT genes for different populations, and analyse correlation to their clinical-pathological characteristics and to the demographics of melanoma. 31274706 2020
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma 		0.500 GeneticVariation disease BEFREE NRAS mutations are the most common alterations among RAS isoforms in cutaneous melanoma, with patients harboring these aggressive tumors having a poor prognosis and low survival rate. 31549767 2020
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma 		0.500 GeneticVariation disease BEFREE Accordingly, in a cohort of 79 BRAF/NRAS double wild type cutaneous melanoma and 17 mucosal melanoma KIT mutation was assessed by Sanger sequencing of exons 9,11,13,17 and 18. 31848942 2020
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.400 GeneticVariation group BEFREE Additionally, the specific p.G12R NRAS mutation in this case is a common somatic mutation in cancer cells, and analysis of previously reported NRAS-RASopathy cases suggests that mutations at traditionally oncogenic codons are associated with elevated cancer risk not present with mutations at other sites. 31697451 2020
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.400 GeneticVariation group BEFREE The three RAS genes (HRAS, NRAS, and KRAS) comprise the most frequently mutated oncogene family in human cancer. 31815779 2020
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.400 GeneticVariation disease BEFREE Our findings underline the likely importance of NRAS gene rs2273267 A>T in the risk of neuroblastoma. 31759987 2020
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.200 Biomarker group BEFREE Patients with tumours harbouring mutation of TP53 and either KRAS or NRAS (32%) had a worse 5-year PFS than those with TP53/KRAS/NRAS wild-type tumours (54% vs. 72%, HR 1.75, p = 0.02). 31199501 2020
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.100 AlteredExpression disease BEFREE The association between high N-RAS levels and the most aggressive among breast cancer subtypes, the triple-negative phenotype, for which targeted approaches are still lacking, underlines the need to further investigate the RAS family. 31646390 2020
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.100 Biomarker phenotype BEFREE Intra-patient heterogeneity was detected in 13.3% of patients for both BRAF and NRAS genes and was not associated with clinico-pathological characteristics of melanomas or metastases. 31774543 2020
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.100 GeneticVariation phenotype BEFREE The presence of mutations of BRAF, NRAS, and KIT genes is recognized as playing a role during carcinogenesis. 31274706 2020
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.100 AlteredExpression disease BEFREE The association between high N-RAS levels and the most aggressive among breast cancer subtypes, the triple-negative phenotype, for which targeted approaches are still lacking, underlines the need to further investigate the RAS family. 31646390 2020
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 GeneticVariation disease BEFREE Our findings underline the likely importance of NRAS gene rs2273267 A>T in the risk of neuroblastoma. 31759987 2020
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 GeneticVariation group BEFREE Additionally, the specific p.G12R NRAS mutation in this case is a common somatic mutation in cancer cells, and analysis of previously reported NRAS-RASopathy cases suggests that mutations at traditionally oncogenic codons are associated with elevated cancer risk not present with mutations at other sites. 31697451 2020
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 GeneticVariation group BEFREE The three RAS genes (HRAS, NRAS, and KRAS) comprise the most frequently mutated oncogene family in human cancer. 31815779 2020
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm 		0.100 Biomarker group BEFREE Intra-patient heterogeneity was detected in 13.3% of patients for both BRAF and NRAS genes and was not associated with clinico-pathological characteristics of melanomas or metastases. 31774543 2020
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.100 GeneticVariation disease BEFREE Our findings underline the likely importance of NRAS gene rs2273267 A>T in the risk of neuroblastoma. 31759987 2020
CUI: C4722085
Disease: Malignant neoplasm of colon and/or rectum
Malignant neoplasm of colon and/or rectum 		0.100 GeneticVariation disease BEFREE Current clinical guidelines recommend mutation analysis for select codons in KRAS and NRAS exons 2, 3, and 4 and BRAF V600E to guide therapy selection and prognostic stratification in advanced colorectal cancer. 31589789 2020
CUI: C0206656
Disease: Embryonal Rhabdomyosarcoma
Embryonal Rhabdomyosarcoma 		0.030 GeneticVariation disease BEFREE We present the case of a germline heterozygous NRAS mutation producing a severe phenotype involving embryonal rhabdomyosarcoma, severe intellectual disability, and numerous melanocytic nevi in addition to more typical manifestations of Noonan syndrome. 31697451 2020
CUI: C0279612
Disease: Childhood Embryonal Rhabdomyosarcoma
Childhood Embryonal Rhabdomyosarcoma 		0.020 GeneticVariation disease BEFREE We present the case of a germline heterozygous NRAS mutation producing a severe phenotype involving embryonal rhabdomyosarcoma, severe intellectual disability, and numerous melanocytic nevi in addition to more typical manifestations of Noonan syndrome. 31697451 2020